Webcast/CME - The Conundrum of Rash in Management of EGFR Inhibitors

	Unregistered User Click here if this is not your Personal Edition
		Contact Us \| Free E-Mail Updates \| Journals \| Register a colleague

Oncology Other

EXPLORE :

Most Read News

All Webcasts / CME

Warning | Privacy

Recent webcasts/CME - Oncology Other

Recent news - Oncology Other

	Endocrine Society Responds to Insulin Glargine Studies With Recommendations - (DGNews)
	Everolimus Is an Effective Treatment Option for Patients With Pancreatic Neuroendocrine Tumours: Presented at ESMO-GI - (DGDispatch)
	Second Gene Linked to Familial Testicular Cancer - (DGNews)
	Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers - (N Engl J Med)
	Bariatric Surgery Could Lower Cancer Risk in Obese Women - (DGNews)

Recent cases - Oncology Other

	Spontaneous Regression in Alveolar Soft Part Sarcoma: Case Report and Literature Review
	Bilateral Swollen Eyelids Occurring During Adjuvant Treatment with Tamoxifen for Early Breast Cancer
	Synchronous Lingual and Thyroid Metastasis from Renal Cell Carcinoma
	Mucinous Cystic Neoplasms of the Mesentery: A Case Report and Review of the Literature
	Cardiovascular Magnetic Resonance Diagnosis of Cystic Tumor of the Atrioventricular Node

personal edition > oncology other > webcasts/CME

Webcasts/CME

E-Mail this webcast/CME to a colleague

The Conundrum of Rash in Management of EGFR Inhibitors

Presented by:	ArcMesa Educators
Lecturer	Roy S. Herbst, MD, PhD, Mario Lacouture, MD, Roman Perez-Soler, MD and Sandy Kurtin, RN, MS, AOCN®, NP
Approximate duration:	1 hr.
Summary points:	This audiovisual presentation reviews the dual role of the rash associated with growth factor receptor inhibitor treatment of cancer as a side effect and as clinical surrogate marker for response and/or survival, appropriate timing of early treatment to manage these adverse skin reactions, and recommended dose titration of various components of chemotherapeutic combinations to achieve best patient outcome.
Accreditation:	ArcMesa Educators is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. ArcMesa Educators designates this educational activity for a maximum of 1 AMA PRA Category 1 credit. ArcMesa Educators is accredited by the Accreditation Council for Pharmacy Education as a Provider of continuing pharmacy education. Course UPN #200-000-06-023-H01. Expiration date: October 9, 2007.
Other:

Additional Information